Lates News

According to AI Express, Huayuan Securities released a research report on February 10th, giving Huatai Medical (688617.SH) a "buy" rating. The main reasons for the rating include: 1) Deep layout in cardiovascular intervention, multidimensional product development; 2) Technological changes + import substitution drive industry growth, barrier created by combination of environment + line products; 3) Centralized procurement strengthens the foundation of coronary artery and vascular intervention, and the potential for capacity expansion is expected to be further released. (Daily Economic News)